TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31493013
Drug: Mineral water
Normalized name: mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral water bath plus physical therapy
Study: 31493013
Drug: Mud application
Normalized name: aminophylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Tablet [Mudrane GG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud application procedures plus physical therapy
Study: 31343477
Drug: Smooth saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth saline injection test (S group)
Study: 19808924
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy, exenatide, and daclizumab
Study: 16702822
Drug: Amlodipine besylate
Normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine besylate (5 mg/day)
Study: 12890955
Drug: Tramadol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol alone (20 mg loading dose, continuous infusion of 1 mg/ml tramadol at 8 ml/h)
Study: 12890955
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (20 ml bupivacaine 0.125% loading dose, continuous infusion of 8 ml/h)
Study: 12890955
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tramadol and bupivacaine (20 mg tramadol loading dose, 20 ml bupivacaine 0.125% loading dose, continuous infusion of 1 mg/ml tramadol in 20 ml bupivacaine 0.125% at 8 ml/h)
Study: 10655253
Drug: Nadolol (40-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40-160 mg/d)
Study: 10655253
Drug: Nadolol plus
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol plus isosorbide mononitrate (10-20 mg 3 times per day)
Study: 8737763
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release oxybutynin tablet (10 mg) after a high fat breakfast
Study: 8737763
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release oxybutynin tablet (10 mg) in fasting subjects
Study: 1329480
Drug: Lisinopril, enalapril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, enalapril, captopril, digoxin
Study: 30264745
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 2.5% gel with a low glycemic load diet
Study: 30264745
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 2.5% gel with a normal diet
Study: 25041917
Drug: Drug-eluting balloon
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting balloon (DEB) angioplasty
Study: 20632453
Drug: Interferon-alpha (IFN‐alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN‐alpha) therapy
Study: 16398595
Drug: 2400 mg
Normalized name: pancreatin 2400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 mg Chinese red yeast rice (CRYR)
Study: 10607712
Drug: 480 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 microg granulocyte colony-stimulating factor (G-CSF)
Study: 10607712
Drug: G-CSF in
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF in vitro
Study: 8609227
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (30 ng/kg per min) for 3 hours (EPI-3)
Study: 8609227
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (30 ng/kg per min) for 24 hours (EPI-24)
Study: 8609227
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline before epinephrine infusion)
Study: 1360807
Drug: Mizolastine (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (5, 10, 20, 40 mg p.o.)
Study: 1360807
Drug: Hyoscine butylbromide
Normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine butylbromide (HBB) (40 mg, s.c.)
Study: 31035309
Drug: Cannabigerol (CBG)
Normalized name: cannabigerolate
DrugBank: Cannabigerol (DB14734)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabigerol (CBG) 120 mg/kg
Study: 24408989
Drug: Acute carnosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute carnosine supplementation (20 mg/kg body weight)
Study: 22293891
Drug: Levulan-PDT and
Normalized name: Levulan
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levulan-PDT and placebo (Eucerin as vehicle cream)
Study: 20871168
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone plus birid triple viable
Study: 20871168
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy including Esomeprazole, Amoxicillin, and Furazolidone
Study: 15647778
Drug: Lisinopril (n=22)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (n=22)
Study: 8485789
Drug: Epidural tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural tramadol (100 mg diluted in 10 ml normal saline)
Study: 2712272
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine 10 mg, 20 minutes prior to electroconvulsive therapy
Study: 30414841
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injections into epicardial fat pads
Study: 30414841
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections into epicardial fat pads
Study: 30414841
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injections
Study: 21817198
Drug: NVP XR
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP XR 400 mg once daily (plus placebo)
Study: 21817198
Drug: NVP IR
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP IR 200 mg twice daily (plus placebo)
Study: 19565730
Drug: Acupoint application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint application using Chinese medicine (Zhinanxing, Sanleng, Ezhu) at Zhongji (CV 3), Guanyuan (CV 4), Qihai (CV 6)
Study: 19565730
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Tianqi Tongjing Capsules
Study: 15624744
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg subcutaneous efalizumab weekly for 12 weeks
Study: 15624744
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment with weekly SC efalizumab after Week 12
Study: 15624744
Drug: Extended efalizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended efalizumab therapy
Study: 27725248
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg fludrocortisone, a MR agonist
Study: 25435850
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m2 (standard half hour i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Study: 25435850
Drug: Gemcitabine 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 250 mg/m2 (prolonged 6-hours i.v. infusion on days 1 and 8) + Cisplatin 75 mg/m2 on day 2
Study: 19346279
Drug: Pregabalin (150-450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150-450 mg)
Study: 9863127
Drug: Xinmaitong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinmaitong Capsule (XMTC)
Study: 9863127
Drug: Composite Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite Danshen Tablet (CDT)
Study: 23013888
Drug: Olmesartan (morning-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (morning-dose group)
Study: 23013888
Drug: Olmesartan (evening-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (evening-dose group)
Study: 19682654
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment initiated at the earliest possible stage post injury
Study: 17062304
Drug: Tizanidine capsules
Normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine capsules (8 mg) administered with food
Study: 17062304
Drug: Tizanidine tablets
Normalized name: Tizanidine Tablets
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine tablets (8 mg) administered with food
Study: 17062304
Drug: Tizanidine capsules
Normalized name: Tizanidine Capsules
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine capsules (8 mg) administered in fasting state
Study: 17062304
Drug: Tizanidine tablets
Normalized name: Tizanidine Tablets
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tizanidine tablets (8 mg) administered in fasting state
Study: 12932798
Drug: Pemoline (56.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline (56.25 mg)
Study: 10636414
Drug: Insulin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 1.5 mU/kg per minute
Study: 10636414
Drug: Insulin 3
Normalized name: Pen Needle Insulin 33 gauge 4mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 3 mU/kg per minute
Study: 8864546
Drug: Intranasal pretreatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pretreatment with NPY (20 nmol)
Study: 1346819
Drug: Antiphospholipid antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiphospholipid antibodies (aCEPHA and aCL)
Study: 6397949
Drug: Incision plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision plus curettage and primary suture under antibiotic cover
Study: 29364026
Drug: 4-week progressive
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week progressive home intrinsic foot muscle (IFM) exercise program performed daily
Study: 28419379
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of local anesthetic to myofascial trigger points (MTrPs)
Study: 15543337
Drug: B-vitamins (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (5 mg folic acid, 0.4 mg hydroxycobalamin and 50 mg pyridoxine) daily for 8 weeks
Study: 9124839
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (1,000 mg)
Study: 2174933
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (group 2)
Study: 7013960
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with diethylstilbestrol, cyclophosphamide, and 5‐fluorouracil (DES + CTx + FU)
Study: 7013960
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (DES leads to CTx + FU)
Study: 22456300
Drug: semagacestat 140
Normalized name: Semagacestat
DrugBank: Semagacestat (DB12463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: semagacestat 140 mg
Study: 22456300
Drug: semagacestat 280
Normalized name: Semagacestat
DrugBank: Semagacestat (DB12463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: semagacestat 280 mg
Study: 10440399
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml)
Study: 1980464
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs (Lormetazepam and Flurazepam)
Study: 28865911
Drug: Trauma Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma Management Therapy (TMT; VRET plus a group treatment for anger, depression, and social isolation)
Study: 29336615
Drug: Ornibel® (etonogestrel/ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornibel® (etonogestrel/ethinylestradiol 11.00/3.47 mg)
Study: 29336615
Drug: Nuvaring® (etonogestrel/ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg)
Study: 23812209
Drug: NexGen LPS
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: NexGen LPS Gender Solutions (GS) prosthesis
Study: 19493153
Drug: ICD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICD plus appropriate medical therapy
Study: 17074344
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (0.2 mg)
Study: 12101821
Drug: Regular exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular exercise and low fat diet (walking 60 minutes daily, <20% total fat, 300 mg/d cholesterol)
Study: 9773699
Drug: ISBPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISBPB with 10 mL 0.125% bupivacaine with epinephrine 1:400,000 (n = 15)
Study: 9791777
Drug: Standard approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard approach to postoperative analgesia (intramuscular injections on an 'as needed' basis)
Study: 410298
Drug: Low-dose Rho(D)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Rho(D) immune globulin (human)
Study: 410298
Drug: Single low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single low-dose immune globulin preparations
Study: 26361969
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg oral, twice a day for a maximum of 4 years)
Study: 26361969
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice a day for a maximum of 4 years)
Study: 23574730
Drug: Miglitol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (150 mg/day)
Study: 18449573
Drug: Double lumen
Normalized name: SOLUPICC 7-Day Double Lumen PICC Line Supply Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double lumen totally implantable subcutaneous port system (PORT)
Study: 17109447
Drug: Cisplatin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with paclitaxel (70 mg/m2)
Study: 17109447
Drug: Cisplatin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with vinorelbine (25 mg/m2)
Study: 11723527
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 microg administered twice daily via a breath‐activated, multi‐dose, dry‐powder inhaler
Study: 2730857
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of total doses delivered
Study: 30133324
Drug: Mice undergoing
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mice undergoing reloading after hindlimb suspension.
Study: 21538524
Drug: Levetiracetam (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (up to 2000 mg per day)
Study: 14520143
Drug: Linezolid 10
Normalized name: LINEZOLID 100MG/5ML SUSP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 10 mg/kg iv every 8 h (with option to switch to oral linezolid 10 mg/kg every 8 h)
Study: 14520143
Drug: Vancomycin 10
Normalized name: vancomycin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 10 to 15 mg/kg every 6 to 24 h
Study: 11090730
Drug: succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1.5 mg/kg
Study: 11090730
Drug: rocuronium bromide
Normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rocuronium bromide 0.6 mg/kg
Study: 8982415
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water iontophoresis in addition to two-sided steroid-free topical therapy
Study: 31091508
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.6 mg/kg)
Study: 28779006
Drug: TREX dosing
Normalized name: L-m-trex
DrugBank: CH-1504 L-isomer (DB19052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TREX dosing
Study: 28779006
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing transitioned to PRN
Study: 27599170
Drug: Massage with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage with lotion
Study: 27599170
Drug: Massage without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Massage without lotion
Study: 24667391
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (1.2 μg kg(‐1) min(‐1))
Study: 24667391
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose remifentanil (0.2 μg kg(‐1) min(‐1))
Study: 22464116
Drug: Pilates-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates-based therapy
Study: 31525673
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control condition (n = 50) consisting of 24 one-hour sessions addressed twice a week
Study: 29056103
Drug: Targeted dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted dietary advice solutions developed per metabotype using a decision tree approach.
Study: 21102369
Drug: Topical proparacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical proparacaine
Study: 11448899
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 25 mg HRS‐3/A9 for 4 days
Study: 11448899
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of 25 mg HRS‐3/A9 every other day
Study: 11448899
Drug: HRS‐3/A9 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS‐3/A9 treatment
Study: 9602194
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (≤ 20 ppm for 1 to 4 days)
Study: 2662065
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release naproxen (Naprosyn CR), 750 mg daily
Study: 2662065
Drug: Standard Naprosyn,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Naprosyn, 750 mg daily
Study: 23649997
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with temozolomide (TMZ) - 200 mg/m² for 5 days post-surgery, followed by 75 mg/m² daily during radiotherapy, and 150-200 mg/m² for 5 days every 28 days after radiotherapy.
Study: 23649997
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone - involved-field radiotherapy in 2 Gy fractions daily for 6 weeks (total of 60 Gy).
Study: 16809799
Drug: Lanthanum chloride
Normalized name: LANTHANUM CHLORIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanthanum chloride (LaCl3) intravenous infusion (120 microg elemental lanthanum over a 4-hour period)
Study: 16809799
Drug: Chewable lanthanum
Normalized name: lanthanum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewable lanthanum carbonate (La2(CO3)3) tablets (1-g oral dose; 4 x 250 mg elemental lanthanum)
Study: 9284854
Drug: Indomethacin (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.20 mg/kg every 12 hours) + Furosemide (1 mg/kg)
Study: 9284854
Drug: Indomethacin (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.20 mg/kg every 12 hours)
Study: 3455968
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of AA per day for two weeks
Study: 3455968
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg (placebo) per day for four weeks
Study: 3455968
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg per day for three weeks
Study: 3455968
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg per day for four weeks
Study: 15752096
Drug: Zinc tablets
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc tablets
Study: 15752096
Drug: Chlorhexidine tablets
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine tablets and mouthwash
Study: 12677364
Drug: Cyclosporine-based immunosuppressive
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine-based immunosuppressive therapy
Study: 8799424
Drug: RO‐11 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO‐11 at a daily s.c. dose of 2,500 anti‐FXa IU
Study: 8799424
Drug: Calcium unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium unfractionated heparin (UH) at a s.c. dose of 5,000 IU 12 hourly
Study: 1453197
Drug: Baseline and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline and change in scores for physical well-being (PWB), mood, pain, and QLI after the first three treatment cycles
Study: 6606942
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of saline placebo
Study: 31006282
Drug: 2-hourly static
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hourly static oral misoprostol
Study: 25847293
Drug: Usual Care:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care: standard intervention provided by the quitline, including brief counseling and nicotine replacement therapy